• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Pharma & Human Health

A potential non-invasive stool test and novel therapy for endometriosis

October 16, 2024 Microbiome Times

Promising findings by researchers at Baylor College of Medicine and collaborating institutions could lead to the development of a non-invasive stool test and a new therapy for endometriosis, a painful condition that affects nearly 200 million women […]

Editor's Choice

Exhaling Clues to the Activity of the Microbiome with Owlstone’s Breath Biopsy Technology – An Interview with Dr. Liz Crone

October 15, 2024 Microbiome Times

Have you considered analyzing captured breath to uncover the secrets of microbial metabolism? In this interview, we speak to Dr Liz Crone, Head of Business Development, Research Products & Services for Europe and Asia at breath-based […]

Finance

Lesaffre acquires Altar, an Adaptive Laboratory Evolution start-up from Ginkgo Bioworks

October 7, 2024 Microbiome Times

Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up specializing in Adaptive Laboratory Evolution (ALE). Created in 2017, Altar will complement Lesaffre’s existing know-how […]

Finance

dsm-firmenich completes the sale of yeast extract business to Lesaffre

October 2, 2024 Microbiome Times

dsm-firmenich, innovators in nutrition, health and beauty, today announces the completion of the sale of its yeast extract business to Lesaffre, a global player in fermentation and microorganisms. The sale of the yeast extract business […]

Finance

Ostia Sciences Inc. Secures Seed Investment, Finalizes IP and Prepares Microbiome Technology Prototype 

October 2, 2024 Microbiome Times

Ostia Sciences Inc., a spinout from the University of Toronto specializing in oral and respiratory microbiome solutions, has successfully raised over CAD $1 million in its seed round and secured full intellectual property (IP) transfer […]

Finance

Florey Biosciences spins out of Harvard Wyss Institute to develop a medical food aimed at managing impacts of antibiotic use

October 1, 2024 Microbiome Times

 Florey Biosciences, a synthetic biology company spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, today announced that it has secured pre-seed funding and is unveiling its lead program, a probiotic […]

Editor's Choice

EMIH and MTIG join forces with Microbiome Times on important deal-making event, taking place Brussels 2025

September 25, 2024 Microbiome Times

Microbiome Times Magazine, the microbiome industry’s leading B2B publication, is pleased to announce its collaboration with the coalition groups European Microbiome Innovation for Health (EMIH) and Microbiome Therapeutics Innovation Group (MTIG) for its upcoming Microbiome […]

Pharma & Human Health

Next-Generation Sequencing for Microbial Community Profiling

September 25, 2024 Microbiome Times

On-Demand Webinar Learn about utilizing next-generation sequencing (NGS) to analyze the genetic diversity and function of complex microbial communities. Compared to culture-based methods, powerful techniques like metagenomics and metatranscriptomics can provide a more comprehensive and […]

No Picture
Webinar

Microbial Community Profiling Webinar

September 25, 2024 Microbiome Times

To learn more about how microbial profiling is being used to study human disease, visit the Illumina Metagenomics page.

Pharma & Human Health

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy

September 24, 2024 Microbiome Times

GN Corporation’s Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne […]

Finance

Abolis Biotechnologies Secures €35M to Accelerate R&D in Innovative Biomanufacturing & Microbiome Solutions

September 19, 2024 Microbiome Times

Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, announced the closing of a €35 million financing round led by an international consortium of investors. This funding will fuel the company’s expansion into global […]

Posts navigation

« 1 … 6 7 8 … 77 »

Sign Up to Free Newsletter

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter